Name: Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression (Video) | JoVE Journal
Uploaded: 2019-01-19T13:00:00.000+00:00
Duration: 6 min 3 s
Description: Learn orthotopic transplantation of syngeneic lung adenocarcinoma cells to study PD-L1 expression in immunocompetent mice. This refined model enables physiological tumor research with gene editing capabilities.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

The authors would like to thank Safia Zahma for her help with the preparation of tissue sections.

All experimental protocols as outlined below follow ethical guidelines and were approved by the Austrian Federal Ministry of Science, Research and Economy.
NOTE: The protocol here describes an orthotopic transplantation model of mouse lung adenocarcinoma cells into syngeneic recipients. Cells may be isolated from tumor-bearing lungs of KrasLSL-G12D:p53fl/fl (KP) mice7,18, if available in-house, and transplanted into mice of the same background and sex. If cells were provided from other research groups and the exact background remains unknown, we recommend the use of the F1 generation of a cross between C57BL/6 and 129S mice as transplant recipients to guarantee maximal tolerance.
1. Cell Preparation
<ol>
	<li>Seed KP cells 24 h before transplantation at approximately 50% confluency in RPMI supplemented with 10% fetal calf serum (FCS), glutamine, and 100 U/mL penicillin and 100 &#956;g/mL streptomycin (hereafter referred to as standard culture medium). Incubate the cell cultures at 37&#176; C, 5% CO2, and around 95% relative humidity.</li>
	<li>On the next day, harvest cells using 1 mL of trypsin-EDTA (0.05% in phosphate-buffered saline [PBS]) for 5 min per 10 cm plate and, subsequently, resuspend detached cells with 9 mL of standard culture medium.</li>
	<li>Count the cells in a hemocytometer and transfer the number of cells needed for the experiments in a 50-mL conical centrifuge tube. 
	NOTE: We recommend transplanting between 2.5 x 105 and 1 x 106 KP cells per mouse, but this might be adapted based on the researcher&#39;s needs.</li>
	<li>Subsequently, centrifuge the cells for 5 min at 300 x g, aspirate the supernatant, and, using a pipette, resuspend the cells at a density of 2 x 107/mL (for the inhalation of 1 x 106 KP cells per mouse) in serum and antibiotic-free RPMI, supplemented with 0.01 M ethylenediaminetetraacetic acid (EDTA).</li>
	<li>Keep the cells on ice until transplantation.</li>
</ol>
2. Orthotopic Transplantation via Intratracheal Delivery
<ol>
	<li>Sedate a mouse (8 - 12 weeks of age) by a subcutaneous injection of a mixture of ketamine (100 mg/kg of body weight) and xylazine (10 mg/kg of body weight).</li>
	<li>While the anesthesia sets in, prepare the catheter for intubation. Therefore, blunt the needle of a catheter by simply cutting the end with scissors. Afterward, push the catheter completely over the end of the needle.</li>
	<li>Confirm the appropriate level of anesthesia by pedal reflex via firm toe pinching and apply ophthalmic ointment to the eyes.</li>
	<li>Fix the mouse on the intubation platform (Figure 1A) by hooking its upper incisors over a suture and confirm that the chest is vertical underneath the suture.</li>
	<li>Place a fiber optic cable in between the front legs to illuminate the chest (Figure 1B).</li>
	<li>Carefully open the mouth of the mouse and pull out the tongue using disinfected flat forceps. Look for the emission of white light to locate the larynx and visualize the epiglottis and arytenoid cartilages (Figure 1C).</li>
	<li>Once the opening of the trachea is clearly visible, gently slide the catheter into the trachea (Figure 1D). The length of the catheter to be inserted depends on the age and size of the animal, since it should not go below the bifurcation to guarantee an even distribution of the lung adenocarcinoma cells within the lung. Quickly remove the needle from the catheter.</li>
	<li>The proper placement of the catheter in the trachea is indicated by the white light shining through the catheter (Figure 1E). In order to confirm the placement of the catheter in the trachea, attach a 1-mL syringe containing water to the catheter. The water in the syringe will rapidly move up and down in accordance with the breathing (Figure 1F). 
	NOTE: This step can be omitted by experienced researchers.</li>
	<li>Warm up the cell suspension by holding the tube in hand and, subsequently, pipette 50 &#181;L of the suspension containing 1 x 106 cells (the number of cells may be variable) into the center of the catheter hub. The suspension will be aspirated immediately. Subsequently, attach a 1 mL syringe and dispense 300 &#181;L of air to assure a consistent distribution within the lungs.</li>
	<li>Gently remove the catheter, remove the mouse from the intubation platform, and put it on a heat pad until it recovers from the anesthesia.</li>
</ol>
3. Lung Preparation for Flow Cytometry
<ol>
	<li>At the desired experimental endpoint, sedate the mouse by a subcutaneous injection of a mixture of ketamine (100 mg/kg of body weight) and xylazine (10 mg/kg of body weight) and euthanize it by cervical dislocation.</li>
	<li>Soak the carcass in 70% ethanol and secure the mouse on a dissection board using tape.</li>
	<li>Make a ventral midline incision and gently invert the skin to expose the thoracic wall muscles and the abdominal organs. Puncture the diaphragm and cut the ribs with scissors to expose the thoracic cavity.</li>
	<li>Perfuse the lungs 3x with 6 - 8 mL of ice-cold PBS through the right ventricle using a 27 G needle after cutting a small opening in the left ventricle to allow blood to leave. The lungs should be cleared of blood and turn completely white.</li>
	<li>Take out the lungs and mince the lobes into small pieces using scissors. Transfer the lung pieces to a 2 mL microcentrifuge tube and incubate it in 1.5 mL of lung digestion buffer (RPMI, 5% FCS, 150 U/mL collagenase I, and 50 U/mL DNase I).</li>
	<li>Incubate the lung pieces 30 - 60 min at 37 &#176;C and with constant shaking.</li>
	<li>Transfer the lung cell suspension through a 70 &#181;m cell strainer into a 50 mL tube. Clear the strainer with the back of a sterile 10-mL syringe and rinse the strainer with 15 mL of PBS with 2% FCS.</li>
	<li>Centrifuge the cells at 300 x g for 5 min at 4 &#176;C and aspirate the supernatant. Resuspend the cells in 1 mL of ammonium-chloride-potassium (ACK) lysing buffer and incubate them for 5 min at room temperature for the lysis of residual erythrocytes.</li>
	<li>Centrifuge the cells at 300 x g for 5 min at 4 &#176;C and resuspend the cells in 1 mL of PBS with 2% FCS and proceed with the desired staining protocol for flow cytometry23. 
	NOTE: Alternatively, the cells may be resuspended in RPMI containing 30% FCS and 10% DMSO and frozen using a freezing container for later analysis.</li>
</ol>

<ol><li>Siegel, R. L., Miller, K. D., Jemal, A. <a target="_blank" href="https://www.ncbi.nlm.nih.gov/pubmed/29313949">Cancer statistics, 2018.</a> CA: A Cancer Journal for Clinicians. 68 (1), 7-30 (2018).</li>
<li>Zappa, C., Mousa, S. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Non-small+cell+lung+cancer%3A+current+treatment+and+future+advances%5BTitle%5D)+AND+%22Translational+Lung+Cancer+Research%22%5BJournal%5D)">Non-small cell lung cancer: current treatment and future advances.</a> Translational Lung Cancer Research. 5 (3), 288-300 (2016).</li>
<li>Dolly, S. O., Collins, D. C., Sundar, R., Popat, S., Yap, T. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Advances+in+the+Development+of+Molecularly+Targeted+Agents+in+Non-Small-Cell+Lung%5BTitle%5D)+AND+%22Drugs%22%5BJournal%5D)">Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung.</a> Drugs. 77 (8), 813-827 (2017).</li>
<li>Stinchcombe, T. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Targeted+Therapies+for+Lung+Cancer%5BTitle%5D)+AND+%22Cancer+Treatment+Research%22%5BJournal%5D)">Targeted Therapies for Lung Cancer.</a> Cancer Treatment Research. 170, 165-182 (2016).</li>
<li>Brody, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((PD-L1+expression+in+advanced+NSCLC%3A+Insights+into+risk+stratification+and+treatment+selection+from+a+systematic+literature+review%5BTitle%5D)+AND+%22Lung+Cancer%22%5BJournal%5D)">PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.</a> Lung Cancer. 112, 200-215 (2017).</li>
<li>Safari, R., Meuwissen, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Practical+use+of+advanced+mouse+models+for+lung+cancer%5BTitle%5D)+AND+%22Methods+in+Molecular+Biology%22%5BJournal%5D)">Practical use of advanced mouse models for lung cancer.</a> Methods in Molecular Biology. 1267, 93-124 (2015).</li>
<li>DuPage, M., Dooley, A. L., Jacks, T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Conditional+mouse+lung+cancer+models+using+adenoviral+or+lentiviral+delivery+of+Cre+recombinase%5BTitle%5D)+AND+%22Nature+Protocols%22%5BJournal%5D)">Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase.</a> Nature Protocols. 4 (7), 1064-1072 (2009).</li>
<li>Kwon, M. C., Berns, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mouse+models+for+lung+cancer%5BTitle%5D)+AND+%22Molecular+Oncology%22%5BJournal%5D)">Mouse models for lung cancer.</a> Molecular Oncology. 7 (2), 165-177 (2013).</li>
<li>Hidalgo, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Patient-derived+xenograft+models%3A+an+emerging+platform+for+translational+cancer+research%5BTitle%5D)+AND+%22Cancer+Discovery%22%5BJournal%5D)">Patient-derived xenograft models: an emerging platform for translational cancer research.</a> Cancer Discovery. 4 (9), 998-1013 (2014).</li>
<li>Chen, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((An+orthotopic+model+of+lung+cancer+to+analyze+primary+and+metastatic+NSCLC+growth+in+integrin+alpha1-null+mice%5BTitle%5D)+AND+%22Clinical+%26+Experiment+Metastasis%22%5BJournal%5D)">An orthotopic model of lung cancer to analyze primary and metastatic NSCLC growth in integrin alpha1-null mice.</a> Clinical & Experiment Metastasis. 22 (2), 185-193 (2005).</li>
<li>Kang, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Development+of+an+orthotopic+transplantation+model+in+nude+mice+that+simulates+the+clinical+features+of+human+lung+cancer%5BTitle%5D)+AND+%22Cancer+Science%22%5BJournal%5D)">Development of an orthotopic transplantation model in nude mice that simulates the clinical features of human lung cancer.</a> Cancer Science. 97 (10), 996-1001 (2006).</li>
<li>Kang, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Proliferation+of+human+lung+cancer+in+an+orthotopic+transplantation+mouse+model%5BTitle%5D)+AND+%22Experimental+and+Therapeutic%22%5BJournal%5D)">Proliferation of human lung cancer in an orthotopic transplantation mouse model.</a> Experimental and Therapeutic. 1 (3), 471-475 (2010).</li>
<li>Kuo, T. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Orthotopic+reconstitution+of+human+small-cell+lung+carcinoma+after+intravenous+transplantation+in+SCID+mice%5BTitle%5D)+AND+%22Anticancer+Research%22%5BJournal%5D)">Orthotopic reconstitution of human small-cell lung carcinoma after intravenous transplantation in SCID mice.</a> Anticancer Research. 12 (5), 1407-1410 (1992).</li>
<li>Li, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+novel+bioluminescence+orthotopic+mouse+model+for+advanced+lung+cancer%5BTitle%5D)+AND+%22Radiation+Research%22%5BJournal%5D)">A novel bioluminescence orthotopic mouse model for advanced lung cancer.</a> Radiation Research. 176 (4), 486-493 (2011).</li>
<li>Mase, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Intrabronchial+orthotopic+propagation+of+human+lung+adenocarcinoma--characterizations+of+tumorigenicity%2C+invasion+and+metastasis%5BTitle%5D)+AND+%22Lung+Cancer%22%5BJournal%5D)">Intrabronchial orthotopic propagation of human lung adenocarcinoma--characterizations of tumorigenicity, invasion and metastasis.</a> Lung Cancer. 36 (3), 271-276 (2002).</li>
<li>McLemore, T. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Novel+intrapulmonary+model+for+orthotopic+propagation+of+human+lung+cancers+in+athymic+nude+mice%5BTitle%5D)+AND+%22Cancer+Research%22%5BJournal%5D)">Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice.</a> Cancer Research. 47 (19), 5132-5140 (1987).</li>
<li>Tsai, L. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+MZF1%2Fc-MYC+axis+mediates+lung+adenocarcinoma+progression+caused+by+wild-type+lkb1+loss%5BTitle%5D)+AND+%22Oncogene%22%5BJournal%5D)">The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss.</a> Oncogene. 34 (13), 1641-1649 (2015).</li>
<li>Winslow, M. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Suppression+of+lung+adenocarcinoma+progression+by+Nkx2-1%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Suppression of lung adenocarcinoma progression by Nkx2-1.</a> Nature. 473 (7345), 101-104 (2011).</li>
<li>Zou, Y., Fu, H., Ghosh, S., Farquhar, D., Klostergaard, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Antitumor+activity+of+hydrophilic+Paclitaxel+copolymer+prodrug+using+locoregional+delivery+in+human+orthotopic+non-small+cell+lung+cancer+xenograft+models%5BTitle%5D)+AND+%22Clinical+Cancer+Research%22%5BJournal%5D)">Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.</a> Clinical Cancer Research. 10 (21), 7382-7391 (2004).</li>
<li>Buckle, T., van Leeuwen, F. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Validation+of+intratracheal+instillation+of+lung+tumour+cells+in+mice+using+single+photon+emission+computed+tomography%2Fcomputed+tomography+imaging%5BTitle%5D)+AND+%22Lab+Animal%22%5BJournal%5D)">Validation of intratracheal instillation of lung tumour cells in mice using single photon emission computed tomography/computed tomography imaging.</a> Lab Animal. 44 (1), 40-45 (2010).</li>
<li>Berry-Pusey, B. N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+semi-automated+vascular+access+system+for+preclinical+models%5BTitle%5D)+AND+%22Physics+in+Medicine+%26+Biology%22%5BJournal%5D)">A semi-automated vascular access system for preclinical models.</a> Physics in Medicine & Biology. 58 (16), 5351-5362 (2013).</li>
<li>Ran, F. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Genome+engineering+using+the+CRISPR-Cas9+system%5BTitle%5D)+AND+%22Nature+Protocols%22%5BJournal%5D)">Genome engineering using the CRISPR-Cas9 system.</a> Nature Protocols. 8 (11), 2281-2308 (2013).</li>
<li>Singer, B. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Flow-cytometric+method+for+simultaneous+analysis+of+mouse+lung+epithelial%2C+endothelial%2C+and+hematopoietic+lineage+cells%5BTitle%5D)+AND+%22American+Journal+of+Physiology+-+Lung+Cellular+and+Molecular+Physiology%22%5BJournal%5D)">Flow-cytometric method for simultaneous analysis of mouse lung epithelial, endothelial, and hematopoietic lineage cells.</a> American Journal of Physiology - Lung Cellular and Molecular Physiology. 310 (9), L796-L801 (2016).</li>
<li>Moll, H. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Afatinib+restrains+K-RAS-driven+lung+tumorigenesis%5BTitle%5D)+AND+%22Science+Translational+Medicine%22%5BJournal%5D)">Afatinib restrains K-RAS-driven lung tumorigenesis.</a> Science Translational Medicine. 10 (446), (2018).</li>
<li>Campeau, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+versatile+viral+system+for+expression+and+depletion+of+proteins+in+mammalian+cells%5BTitle%5D)+AND+%22PLoS+One%22%5BJournal%5D)">A versatile viral system for expression and depletion of proteins in mammalian cells.</a> PLoS One. 4 (8), e6529(2009).</li>
<li>Gui, L., Qian, H., Rocco, K. A., Grecu, L., Niklason, L. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Efficient+intratracheal+delivery+of+airway+epithelial+cells+in+mice+and+pigs%5BTitle%5D)+AND+%22American+Journal+of+Physiology+-+Lung+Cellular+and+Molecular+Physiology%22%5BJournal%5D)">Efficient intratracheal delivery of airway epithelial cells in mice and pigs.</a> American Journal of Physiology - Lung Cellular and Molecular Physiology. 308 (2), L221-L228 (2015).</li>
<li>Helms, M. N., Torres-Gonzalez, E., Goodson, P., Rojas, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Direct+tracheal+instillation+of+solutes+into+mouse+lung%5BTitle%5D)+AND+%22Journal+of+Visualized+Experiments%22%5BJournal%5D)">Direct tracheal instillation of solutes into mouse lung.</a> Journal of Visualized Experiments. (42), e1941(2010).</li>
<li>Lin, Y. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Pharmacokinetics%2FPharmacodynamics+of+Pulmonary+Delivery+of+Colistin+against+Pseudomonas+aeruginosa+in+a+Mouse+Lung+Infection+Model%5BTitle%5D)+AND+%22Antimicrobial+Agents+and+Chemotherapy%22%5BJournal%5D)">Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.</a> Antimicrobial Agents and Chemotherapy. 61 (3), (2017).</li>
<li>Wegesser, T. C., Last, J. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Lung+response+to+coarse+PM%3A+bioassay+in+mice%5BTitle%5D)+AND+%22Toxicology+and+Applied+Pharmacology%22%5BJournal%5D)">Lung response to coarse PM: bioassay in mice.</a> Toxicology and Applied Pharmacology. 230 (2), 159-166 (2008).</li>
<li>Cai, Y., Kimura, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Noninvasive+intratracheal+intubation+to+study+the+pathology+and+physiology+of+mouse+lung%5BTitle%5D)+AND+%22Journal+of+Visualized+Experiments%22%5BJournal%5D)">Noninvasive intratracheal intubation to study the pathology and physiology of mouse lung.</a> Journal of Visualized Experiments. (81), e50601(2013).</li>
<li>Lawrenz, M. B., Fodah, R. A., Gutierrez, M. G., Warawa, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Intubation-mediated+intratracheal+%28IMIT%29+instillation%3A+a+noninvasive%2C+lung-specific+delivery+system%5BTitle%5D)+AND+%22Journal+of+Visualized+Experiments%22%5BJournal%5D)">Intubation-mediated intratracheal (IMIT) instillation: a noninvasive, lung-specific delivery system.</a> Journal of Visualized Experiments. (93), e52261(2014).</li>
<li>Vandivort, T. C., An, D., Parks, W. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((An+Improved+Method+for+Rapid+Intubation+of+the+Trachea+in+Mice%5BTitle%5D)+AND+%22Journal+of+Visualized+Experiments%22%5BJournal%5D)">An Improved Method for Rapid Intubation of the Trachea in Mice.</a> Journal of Visualized Experiments. (108), e53771(2016).</li>
</ol>

The authors have nothing to disclose.

To study lung physiologic and pathologic events in the lung, invasive and non-invasive intratracheal intubation methods for the instillation of various reagents are widely used26,27,28,29,30,31,32. In the cancer field, researchers use the intratracheal (and intranasal) instillation of Cre-re...

Lung cancer is still by far the biggest cancer-related killer in both men and women1. Indeed, according to the American Cancer Society, every year more people die of lung cancer than of breast, prostate, and colon cancer together1. Until recently, the majority of patients suffering from non-small cell lung cancer (NSCLC), which is the most abundant subtype of lung cancer, were treated with platinum-based chemotherapy in a first-line setting, mostly with the addition of angiogenesis inhibitors2. Only a subset of patients harbors oncogenic mutations in the epidermal growth factor receptor (EGFR), in anaplastic lymphoma kinase (ALK), or in ROS1, and can be treated with available targeting drugs3,4. With the advent of immune checkpoint inhibitors, new hope for lung cancer patients has arisen, although until now, only 20&#8211;40% of patients respond to immune therapy5. Hence, further research is required to improve this outcome by fine-tuning immune checkpoint therapy and investigating combinatory treatment options.
To study lung cancer, a vast array of preclinical models are available, including spontaneous models triggered by chemicals and carcinogens and genetically engineered mouse models (GEMM) where autochthonous tumors arise following the conditional activation of oncogenes and/or the inactivation of tumor suppressor genes6,7,8. These models are of particular value to investigate fundamental processes in lung tumor development, but they also require extensive mice breeding, and experiments are time-consuming. Therefore, many studies evaluating potential inhibitors take advantage of subcutaneous (patient-derived) xenograft models where human lung cancer cell lines are subcutaneously injected into immunodeficient mice9.
In these models, the micromilieu of tumors is not represented accordingly; hence, researchers also use orthotopic transplantation models, where tumor cells are injected intravenously, intrabronchially, or directly into the lung parenchyma10,11,12,13,14,15,16,17,18,19,20. Some of these methods are technically challenging, difficult to be reproduced, and require intensive training of the researchers.21 Here we adapted a non-invasive orthotopic, intratracheal transplantation method in immunocompetent mice, where tumors develop within 3-5 weeks and exhibit significant similarities to human tumors, to induce the expression of the T-cell suppressor Programmed death-ligand 1 (PD-L1) on tumor cells.11,12,20 The use of mouse tumor cells derived from GEMM models and syngeneic recipient mice allows proper studying of the tumor microenvironment including immune cells. Furthermore, gene editing tools like CRISPR/Cas9 technology22 can be used in vitro before transplantation which facilitates the investigation of the impact of genetic factors in lung tumorigenesis.

<table><tbody><tr><td>mouse lung adenocarcinoma cell line</td><td></td><td></td><td>isolated in house</td></tr><tr><td>C57Bl/6 mice</td><td></td><td></td><td>F1 of the cross of the two backgrounds may be used (8-12 weeks)</td></tr><tr><td>129S mice</td><td></td><td></td><td></td></tr><tr><td>RPMI 1640 Medium</td><td>Life Technologies</td><td>11544446</td><td></td></tr><tr><td>Fetal Calf Serum</td><td>Life Technologies</td><td>11573397</td><td></td></tr><tr><td>Penicillin/Streptomycin Solution</td><td>Life Technologies</td><td>11548876</td><td></td></tr><tr><td>L-Glutamine</td><td>Life Technologies</td><td>11539876</td><td></td></tr><tr><td>Trypsin, 0.25% (1x) with EDTA</td><td>Life Technologies</td><td>11560626</td><td></td></tr><tr><td>UltraPure 0.5 M EDTA, pH 8.0</td><td>Thermo Fisher Scientific</td><td>15575020</td><td></td></tr><tr><td>Ketasol (100 mg/mL Ketamine)</td><td>Ogris Pharma</td><td>8-00173</td><td></td></tr><tr><td>Xylasol (20 mg/mL Xylazine)</td><td>Ogris Pharma</td><td>8-00178</td><td></td></tr><tr><td>BD Insyste (22 GA 1.00 IN)</td><td>BD</td><td>381223</td><td></td></tr><tr><td>Blunt forceps</td><td>Roboz</td><td>RS8260</td><td></td></tr><tr><td>Leica CLS150 LED</td><td>Leica</td><td>30250004</td><td>Fibre Light Illuminator</td></tr><tr><td>Student Iris Scissors</td><td>Fine Science Tools</td><td>91460-11</td><td></td></tr><tr><td>DNase I (RNase-Free)</td><td>New England Biolabs</td><td>M0303S</td><td></td></tr><tr><td>Collagenase Type I</td><td>Life Technologies</td><td>17100017</td><td></td></tr><tr><td>ACK Lysing Buffer</td><td>Lonza</td><td>10-548E</td><td></td></tr><tr><td>CD274 (PD-L1, B7-H1) Monoclonal Antibody (MIH5), PE-Cyanine7</td><td>eBioscience</td><td>25-5982-82</td><td></td></tr><tr><td>Rat IgG2a kappa Isotype Control, PE-Cyanine7</td><td>eBioscience</td><td>25-4321-82</td><td></td></tr></tbody></table>

orthotopic transplantation of syngeneic lung adenocarcinoma cells to study pd-l1 expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

The use of mouse models is indispensable for studying the pathophysiology of various diseases. With respect to lung cancer, several models are available, including genetically engineered models as well as transplantation models. However, genetically engineered mouse models are time-consuming and expensive, whereas some orthotopic transplantation models are difficult to reproduce. Here, a non-invasive intratracheal delivery method of lung tumor cells as an alternative orthotopic transplantation model is described. The use of mouse lung adenocarcinoma cells and syngeneic graft recipients allows studying tumorigenesis under the presence of a fully active immune system. Furthermore, genetic manipulations of tumor cells before transplantation makes this model an attractive time-saving approach to study the impact of genetic factors on tumor growth and tumor cell gene expression profiles under physiological conditions. Using this model, we show that lung adenocarcinoma cells express increased levels of the T-cell suppressor programmed death-ligand 1 (PD-L1) when grown in their natural environment as compared to cultivation in vitro.

We used the orthotopic transplantation model via intratracheal tumor cell delivery to test whether the tumor microenvironment stimulates PD-L1 expression. Therefore, we isolated mouse lung AC cells from the autochthonous KP model (KP cells), 10 weeks following tumor induction via Cre-recombinase-expressing adenovirus (Ad.Cre) delivery24. Subsequently, we labeled the lung AC cells using a green fluorescent protein (GFP)-expressing lentivirus25</sup...

Here we describe a minimally invasive syngeneic orthotopic transplantation model of mouse lung adenocarcinoma cells as a time- and cost-reducing model to study non-small cell lung cancer.

The use of mouse models is indispensable for studying the pathophysiology of various diseases. With respect to lung cancer, several models are available, ...

orthotopic-transplantation-syngeneic-lung-adenocarcinoma-cells-to

Research

JoVE Journal

Cancer Research

A method for reliably grafting luciferase-tagged human malignant peripheral nerve sheath tumor cells into the sciatic nerve of immunodeficient mice is described.  The use of bioluminescence imaging to demonstrate proper establishment of tumor grafts and criteria for random segregation of animals into study groups are also discussed.

Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents

This video describes the preparation of mouse lung cell suspension for flow cytometric analysis to study PD-L1 expression of lung adenocarcinoma cells.

Mouse Lung Preparation for Flow Cytometry: Generating Cell Suspension from Lung Tissue for Flow Cytometric Analysis

The video explains a stepwise surgical method for orthotopic implantation of a tumor fragment from a cancerous donor to the pancreas of a non-cancerous recipient mice for development of pancreatic cancer. Orthotopically implanted PDAC could recapture the tissue microenvironment of human pancreatic cancers than conventional subcutaneous (SC) models more accurately.

Orthotopic Homograft Tumor Transplantation: A Technique to Generate Pancreatic Tumor Mouse Models

We describe a method to significantly enhance orthotopic engraftment of lung cancer cells into the murine lungs by pre-conditioning the airways with injury. This approach may also be applied to study stromal interactions within the lung microenvironment, metastatic dissemination, lung cancer co-morbidities, and to more efficiently generate patient derived xenografts.

Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment

The experimental procedure on the immunophenotyping of murine orthotopic PDAC homografts aims at profiling the tumor immuno-microenvironment. Tumors are orthotopically implanted via surgery. Tumors of 200–600 mm3 in size were harvested and dissociated to prepare single-cell suspensions, followed by multi-immune marker FACS analysis using different fluorescently-labeled antibodies.

Immunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

We describe a protocol for the ultrasound guided implantation of murine-derived pancreatic ductal adenocarcinoma cell lines directly into the native tumor site. This approach resulted in pancreatic tumors detectable by ultrasound scanning within 2-4 weeks of injection, and significantly reduced the proportion tumor cell seeding on the peritoneal wall as compared to surgical orthotopic implantation.

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Syngeneic mouse orthotopic allografts of pancreatic ductal adenocarcinoma (PDAC) recapitulate the biology, phenotypes, and therapeutic responses of disease subtypes. Owing to their fast, reproducible tumor progression, they are widely used in preclinical studies. Here, we show common practices to generate these models, injecting syngeneic murine PDAC cultures into the pancreas.

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

The present protocol describes the reprogramming of Pancreatic Ductal Adenocarcinoma (PDAC) and normal pancreatic ductal epithelial cells into induced pluripotent stem cells (iPSCs). We provide an optimized and detailed, step-by-step procedure, from preparing lentivirus to establishing stable iPSC lines.

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

This study presents an orthotopic non-small cell lung cancer (NSCLC) model based on intrapulmonary inoculation of multicellular spheroids of fluorescent A549-iRFP cells. The model recapitulates clinical NSCLC stages and responds to cisplatin, according to dynamic in vivo monitoring of long-wavelength fluorescence.

Construction of An Orthotopic Xenograft Model of Non-Small Cell Lung Cancer Mimicking Disease Progression and Predicting Drug Activities

A major challenge of developing new therapies for lung cancer includes modeling the tumor microenvironment as regional disease progresses to metastatic disease. Here, we describe a simple method of establishing an orthotopic syngeneic model of lung cancer that allows for in vivo tracking of disease over time.

A Minimally Invasive Method for Generating a Syngeneic Orthotopic Mouse Model of Lung Cancer

Learn orthotopic transplantation of syngeneic lung adenocarcinoma cells to study PD-L1 expression in immunocompetent mice. This refined model enables physiological tumor research with gene editing capabilities.

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Explore More Videos